NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the underwriter for its recent public offering has exercised an overallotment option to purchase 825,000 additional shares of the company's common stock, bringing the total gross proceeds from the offering to $31.6 million.

Aegis Capital was the sole book-running manager on the offering. Rosetta completed the public offering of 5.5 million shares at $5 per share earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.